248 related articles for article (PubMed ID: 15193072)
1. Clinical evaluation of the oral iron chelator deferiprone for the potential treatment of iron overload in bird species.
Whiteside DP; Barker IK; Mehren KG; Jacobs RM; Conlon PD
J Zoo Wildl Med; 2004 Mar; 35(1):40-9. PubMed ID: 15193072
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic disposition of the oral iron chelator deferiprone in the domestic pigeon (Columba livia).
Whiteside DP; Barker IK; Conlon PD; Tesoro A; Thiessen JJ; Mehren KG; Jacobs RM; Spino M
J Avian Med Surg; 2007 Jun; 21(2):121-9. PubMed ID: 18065133
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic disposition of the oral iron chelator deferiprone in the white leghorn chicken.
Whiteside DP; Barker IK; Conlon PD; Tesoro A; Thiessen JJ; Mehren KG; Jacobs RM; Spino M
J Avian Med Surg; 2007 Jun; 21(2):110-20. PubMed ID: 18065132
[TBL] [Abstract][Full Text] [Related]
4. Liver iron depletion and toxicity of the iron chelator deferiprone (L1, CP20) in the guinea pig.
Wong A; Alder V; Robertson D; Papadimitriou J; Maserei J; Berdoukas V; Kontoghiorghes G; Taylor E; Baker E
Biometals; 1997 Oct; 10(4):247-56. PubMed ID: 9353871
[TBL] [Abstract][Full Text] [Related]
5. Use of deferiprone for the treatment of hepatic iron storage disease in three hornbills.
Sandmeier P; Clauss M; Donati OF; Chiers K; Kienzle E; Hatt JM
J Am Vet Med Assoc; 2012 Jan; 240(1):75-81. PubMed ID: 22171759
[TBL] [Abstract][Full Text] [Related]
6. Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload.
al-Refaie FN; De Silva CE; Wonke B; Hoffbrand AV
J Clin Pathol; 1995 Feb; 48(2):110-4. PubMed ID: 7745107
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation therapy.
Hoffbrand AV; Wonke B
J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
[TBL] [Abstract][Full Text] [Related]
8. The controversial role of deferiprone in the treatment of thalassemia.
Richardson DR
J Lab Clin Med; 2001 May; 137(5):324-9. PubMed ID: 11329529
[TBL] [Abstract][Full Text] [Related]
9. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
[TBL] [Abstract][Full Text] [Related]
11. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R
Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573
[TBL] [Abstract][Full Text] [Related]
14. Orally active iron chelators in the treatment of iron overload.
Olivieri NF
Curr Opin Hematol; 1996 Mar; 3(2):125-30. PubMed ID: 9372062
[TBL] [Abstract][Full Text] [Related]
15. Deferiprone: new preparation. Poorly assessed.
Prescrire Int; 2000 Oct; 9(49):131-5. PubMed ID: 11603411
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the effect of the oral iron chelator deferiprone on asymptomatic Plasmodium falciparum parasitemia in humans.
Thuma PE; Olivieri NF; Mabeza GF; Biemba G; Parry D; Zulu S; Fassos FF; McClelland RA; Koren G; Brittenham GM; Gordeuk VR
Am J Trop Med Hyg; 1998 Mar; 58(3):358-64. PubMed ID: 9546419
[TBL] [Abstract][Full Text] [Related]
17. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major.
Diav-Citrin O; Atanackovic G; Koren G
Ther Drug Monit; 1999 Feb; 21(1):74-81. PubMed ID: 10051057
[TBL] [Abstract][Full Text] [Related]
18. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Ha SY; Chik KW; Ling SC; Lee AC; Luk CW; Lam CW; Ng IO; Chan GC
Hemoglobin; 2006; 30(2):263-74. PubMed ID: 16798652
[TBL] [Abstract][Full Text] [Related]
20. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
Wong CS; Kwok JC; Richardson DR
Biochim Biophys Acta; 2004 Dec; 1739(1):70-80. PubMed ID: 15607119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
